 LOS ALTOS, Calif.--BUSINESS WIRE--RenovoRx, Inc. RenovoRx or the Company Nasdaq: RNXT, a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will present preclinical research supporting its planned second clinical indication, bile duct cancer, also known as cholangiocarcinoma, at the Global Embolization Oncology Symposium Technologies GEST 2022, today in New York City. The study demonstrates the potential utility of RenovoRxs proprietary Tran 